MARKET

CBLI

CBLI

Cleveland Biolbs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.610
+0.080
+5.23%
Closed 16:00 04/08 EDT
OPEN
1.520
PREV CLOSE
1.530
HIGH
1.610
LOW
1.490
VOLUME
121.70K
TURNOVER
--
52 WEEK HIGH
5.00
52 WEEK LOW
0.5000
MARKET CAP
18.19M
P/E (TTM)
-7.6703
1D
5D
1M
3M
1Y
5Y

EPS

CBLI News

More
  • INO, MNK among premarket gainers
  • Seeking Alpha - Article · 03/12 13:16
  • Familiar names up premarket as COVID-19 weighs on market
  • Seeking Alpha - Article · 03/12 10:39
  • 90 Biggest Movers From Yesterday
  • Benzinga · 03/12 10:10
  • 78 Stocks Moving In Wednesday's Mid-Day Session
  • Benzinga · 03/11 16:12

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About CBLI

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
More

Webull offers kinds of Cleveland BioLabs, Inc. stock information, including NASDAQ:CBLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBLI stock news, and many more online research tools to help you make informed decisions.